|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.490 USD | -10.78% |
|
-20.74% | +10.37% |
| 15/01 | Ocugen, Inc. - Special Call | |
| 15/01 | Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 52Cr | - | - | - | ||
| 4.83TCr | |||||
| 4.32TCr | - | - | - | - | - |
| 3.98TCr | |||||
| 3.7TCr | |||||
| 3.07TCr |
- Stock Market
- Equities
- OCGN Stock
- Charts Ocugen, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition